Use of Serum Biomarkers to Predict Cerebral Hypoxia after Severe Traumatic Brain Injury
- 10 April 2012
- journal article
- research article
- Published by SAGE Publications in Journal of Neurotrauma
- Vol. 29 (6) , 1140-1149
Abstract
The management of severe traumatic brain injury (TBI) focuses on prevention and treatment of secondary insults such as cerebral hypoxia (CH). There are a number of biomarkers that are thought to play a part in secondary injury following severe TBI. This study evaluates the association between S100β, neuron-specific enolase (NSE), and glial fibrillary acidic protein (GFAP), detected in the serum of severe TBI patients and CH as measured by brain tissue oxygen partial pressure (Pbo2). Patients with severe TBI were prospectively enrolled. Pressure times time (PTD; mm Hg*h), measuring the depth and duration of CH, was calculated for 12-h periods for episodes of moderate (Pbo2 < 20 mm Hg) and severe (Pbo2 < 15 mm Hg) CH, and compared to serum levels of S100β, NSE, and GFAP drawn prior to periods of monitoring. An adjusted mixed model analysis was applied as was receiver operating characteristic (ROC) curve analysis. Of 76 patients enrolled, 24 had Pbo2 monitoring. One hundred and thirty serum samples were matched with 12-h periods of monitoring. Significant associations were found in adjusted analyses between increasing serum levels of S100β (coefficient=0.57, 0.56; ppp=0.003 and 0.002), and increasing PTD of moderate (Pbo22<15 mm Hg) CH. AUCs for the prediction of moderate and severe CH were 0.62 and 0.66 for S100β, 0.55 and 0.71 for NSE, and 0.50 and 0.62 for GFAP, respectively. Specificities were between 76% and 90% for S100β and NSE. S100β, NSE, and GFAP demonstrate promise as candidate serum markers of impending CH. The fact that these biomarker elevations occur prior to the onset of clinical manifestations suggests that we may be able to predict imminent events following TBI. Given the morbidity of CH, early intervention and prevention may have a significant impact on outcomes and help guide decisions about the timing of interventions.Keywords
This publication has 60 references indexed in Scilit:
- Neuron-Specific Enolase, S100B, and Glial Fibrillary Acidic Protein Levels as Outcome Predictors in Patients With Severe Traumatic Brain InjuryNeurosurgery, 2011
- Validation of Serum Markers for Blood-Brain Barrier Disruption in Traumatic Brain InjuryJournal of Neurotrauma, 2009
- COMPARATIVE STUDY OF DECOMPRESSIVE CRANIECTOMY AFTER MASS LESION EVACUATION IN SEVERE HEAD INJURYNeurosurgery, 2009
- Serum Biomarker Concentrations and Outcome after Pediatric Traumatic Brain InjuryJournal of Neurotrauma, 2007
- Serum Biomarkers after Traumatic and Hypoxemic Brain Injuries: Insight into the Biochemical Response of the Pediatric Brain to Inflicted Brain InjuryDevelopmental Neuroscience, 2006
- Outcome following decompressive craniectomy for malignant swelling due to severe head injuryJournal of Neurosurgery, 2006
- Neuron-Specific Enolase and S100B in Cerebrospinal Fluid After Severe Traumatic Brain Injury in Infants and ChildrenPediatrics, 2002
- S-100 Protein and Neuron-Specific Enolase as Markers of Subclinical Cerebral Damage after Cardiac Surgery: Preliminary Observation of a 6-Month Follow-Up StudyEuropean Neurology, 2001
- Elevated serum levels of S-100 after deep hypothermic arrest correlate with duration of circulatory arrestEuropean Journal of Cardio-Thoracic Surgery, 1996
- Evaluating Trauma Care1987